BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Core Insights - BetterLife Pharma Inc. has appointed Doug Drysdale as Corporate Advisor to advance the development of BETR-001 for non-psychiatric indications, specifically targeting cluster headaches and migraines [1][4] Company Overview - BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic derivative of LSD, for various neurological disorders [5] - BETR-001 is currently in preclinical and IND-enabling studies and is unique in being unregulated, allowing for self-administration [5] - The company holds a synthesis patent for BETR-001, which eliminates regulatory hurdles, and a pending patent covering treatment methods for neurological disorders until around 2042 [5] Leadership and Experience - Doug Drysdale has a proven track record in the biotech industry, having led Cybin from molecule inception to Phase 3 trials in three years [2] - He previously served as Founding CEO of Alvogen, growing the company to $500 million in revenues across 35 countries in 5.5 years [3] - Drysdale has also held leadership roles in other pharmaceutical companies, significantly increasing their enterprise values and revenues [3] Product Development - BETR-001 has shown promise in reducing cluster headache frequency in a small clinical study, indicating its potential effectiveness [4] - The company is also exploring strategic alternatives for the development of another drug candidate aimed at treating viral infections [6]